vTv Therapeutics Inc.
General ticker "VTVT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $115.2M (TTM average)
vTv Therapeutics Inc. follows the US Stock Market performance with the rate: 34.7%.
Estimated limits based on current volatility of 4.5%: low 24.51$, high 26.84$
Factors to consider:
- Total employees count: 16 (+23.1%) as of 2023
- Top business risk factors: Need for additional capital, Regulatory and compliance, Clinical trial failures, Market competition, Litigation risks
- Current price 40.6% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.56$, 19.47$]
- 2025-12-31 to 2026-12-31 estimated range: [5.15$, 15.62$]
Financial Metrics affecting the VTVT estimates:
- Negative: with PPE of -4.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Industry operating cash flow (median)
- Negative: Operating cash flow per share per price, % of -31.16 <= 0.33
- Positive: 18.93 < Shareholder equity ratio, % of 31.88 <= 41.86
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VTVT quotes
Long-term VTVT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2.02MM | $0.00MM | $1.02MM |
| Operating Expenses | $24.56MM | $25.50MM | $25.20MM |
| Operating Income | $-22.54MM | $-25.50MM | $-24.18MM |
| Non-Operating Income | $-2.33MM | $-0.46MM | $1.57MM |
| Interest Expense | $0.01MM | $0.01MM | $0.00MM |
| R&D Expense | $12.36MM | $13.60MM | $11.55MM |
| Income(Loss) | $-24.87MM | $-25.97MM | $-22.61MM |
| Taxes | $0.20MM | $0.00MM | $0.10MM |
| Profit(Loss)* | $-19.16MM | $-20.25MM | $-18.46MM |
| Stockholders Equity | $-10.74MM | $-24.68MM | $12.20MM |
| Assets | $33.24MM | $11.02MM | $38.27MM |
| Operating Cash Flow | $-16.02MM | $-19.08MM | $-25.31MM |
| Capital expenditure | $0.02MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.02MM | $4.40MM | $0.00MM |
| Financing Cash Flow | $14.75MM | $12.00MM | $52.61MM |
| Earnings Per Share** | $-9.98 | $-9.71 | $-3.20 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.